Welcome to our dedicated page for Chimerix news (Ticker: CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.
Chimerix, Inc. (NASDAQ: CMRX) is a pioneering biopharmaceutical company focused on the development of innovative antiviral therapeutics. Led by a team of experienced professionals, Chimerix aims to enhance the quality of life for patients across diverse medical fields, including transplant, oncology, acute care, and global health.
Chimerix leverages its proprietary lipid technology, resulting in two promising clinical-stage compounds: CMX001 and CMX157. These compounds have shown potential for improved activity, bioavailability, and safety over existing drugs. The lead compound, CMX001, is a broad-spectrum antiviral that combats double-stranded DNA (dsDNA) viruses, such as cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus, and variola (smallpox). CMX001 has completed Phase 2 development for CMV prophylaxis and is currently in Phase 2 trials for adenovirus treatment in hematopoietic stem cell transplant (HSCT) recipients.
Chimerix’s portfolio also includes ONC201, an oral, first-in-class small molecule imipridone targeting H3 K27M-mutant gliomas. The Phase 3 ACTION trial for ONC201 is a major focus, enrolling patients at over 130 sites in 13 countries. This study aims to report interim overall survival data by early 2025. Additionally, Chimerix's second-generation compound, ONC206, is undergoing Phase I dose escalation trials, demonstrating anti-cancer activity in both CNS and non-CNS tumors.
Financially, Chimerix maintains a robust balance sheet with significant capital to fund ongoing operations, reflecting sound fiscal management. The company reported a net loss of $18.6 million for Q2 2023 but continues to advance its research and development initiatives.
Chimerix’s mission is to develop medications that significantly improve and extend the lives of patients battling severe diseases. With ongoing clinical trials, strategic financial planning, and a dedicated team, Chimerix is poised to make substantial contributions to global health.
Chimerix (NASDAQ:CMRX) will host a live conference call on May 4, 2023, at 8:30 a.m. ET to report its financial results for Q1 2023, which ended March 31, 2023. The call will provide a business overview alongside the financial disclosures. Investors can participate by calling (646) 307-1963 domestically or (800) 715-9871 internationally, referring to conference ID 8594205. A live audio webcast will also be available on Chimerix's website, with an archived version accessible two hours post-event.
Chimerix is focused on developing medicines for severe diseases, centered around its advanced clinical program, ONC201, aimed at treating H3 K27M-mutant glioma.
Chimerix (NASDAQ:CMRX) recently presented significant findings at the American Association for Cancer Research (AACR) Annual Meeting, showcasing the efficacy of ONC201 against H3 K27M-mutant glioma. The results indicated that patients treated with ONC201 experienced a statistically significant reversal of the negative epigenetic signature associated with this mutation, a first in clinical trials. These findings, supported by preclinical data, highlight ONC201's ability to penetrate the blood-brain barrier and its potential as a therapeutic agent. Ongoing Phase 3 trials, including the ACTION trial, aim to further validate these promising results.
Chimerix (CMRX) reported a strong financial position with $266 million cash and no debt as of December 31, 2022. The company is focused on advancing its oncology pipeline, particularly ONC201 in the Phase 3 ACTION trial for patients with H3 K27M-mutant glioma, with first data expected in early 2025. Chimerix also noted encouraging preliminary findings for ONC206 in treating glioblastoma patients. For 2022, the company achieved net income of $172.2 million, significantly up from a $173.2 million loss in 2021, primarily due to the TEMBEXA sale. The fourth quarter net loss narrowed to $21 million from $39.5 million the previous year.
Chimerix (NASDAQ:CMRX) announced that its CEO, Mike Sherman, will participate in a Targeted Oncology Panel at the Cowen and Company 43rd Annual Health Care Conference on March 7, 2023, at 2:10 p.m. ET. An audio webcast of the discussion will be available on the company's Investor Relations section of their website, where it will remain archived for approximately 90 days.
Chimerix is focused on developing medicines to improve the lives of patients facing serious diseases, with its most advanced program, ONC201, targeting H3 K27M-mutant glioma.
Chimerix (NASDAQ:CMRX) announced it will host a live conference call on March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2022. The conference will provide insights into the company's performance and a business overview.
Participants can join the call by dialing (646) 307-1963 domestically or (800) 715-9871 internationally, using conference ID 9730865. An audio webcast will be accessible in the Investors’ section of Chimerix's website, with an archived version available two hours post-event.
DURHAM, N.C., Jan. 5, 2023 – Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 12:00 p.m. PT in San Francisco, CA.
Investors can access an audio webcast of this presentation on Chimerix's Investor Relations website, where it will be archived for about 90 days. Chimerix focuses on developing medicines that improve the lives of patients with severe diseases, with its leading program, ONC201, targeting H3 K27M-mutant glioma.
Chimerix (CMRX) announced the launch of the ONC201 Phase 3 ACTION study, focusing on its potential approval for treating glioma. Recent analyses showed that patients with recurrent H3 K27M-mutant glioma have a median overall survival (OS) of 5.1 months without ONC201, compared to 13.7 months in earlier Phase 2 data. External studies presented at SNO indicated significant OS benefits for ONC201-treated patients. Following FDA feedback, Chimerix plans to reduce workforce by 25% to streamline oncology efforts, positioning itself for future success in clinical trials.
Chimerix (NASDAQ:CMRX) recently addressed potential liquidation discussions with Rubric Capital Management. The company emphasized its commitment to its Phase 3 neuro-oncology program, ONC201, which targets a significant patient need. Chimerix highlighted its recent sale of TEMBEXA as a funding source for ongoing oncology developments, asserting that liquidation would hinder progress and deprive shareholders of potential gains. The leadership remains optimistic about creating value through continued advancements in their product pipeline, especially with promising Phase 2 data for ONC201.
Rubric Capital Management, owning about 8.5% of Chimerix (CMRX), has expressed concerns regarding the company's strategy and calls for a winddown process. The investment advisor highlights a significant discount of the share price to its liquidation value and urges management to conserve cash while exploring strategic alternatives for ONC201. They estimate a liquidation value of $2.95 to $4.36 per share, implying a potential return of 52% to 125% based on recent prices. Rubric emphasizes the urgent need for cost reduction and a change in direction to protect shareholder value.
FAQ
What is the current stock price of Chimerix (CMRX)?
What is the market cap of Chimerix (CMRX)?
What does Chimerix, Inc. do?
What are Chimerix's leading compounds?
What stages are Chimerix's clinical trials in?
How is Chimerix financially positioned?
What is the significance of the ONC201 Phase 3 ACTION trial?
What kind of partnerships does Chimerix have?
Where is Chimerix based?
How does Chimerix generate revenue?
What is unique about Chimerix’s lipid technology?
What is Chimerix's mission?
